Related Experiment Videos
Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA
R Bauernschmitt1, H Böhrer, S Hagl
1Department of Cardiac Surgery, University of Heidelberg, Germany.
Insights
C1-esterase inhibitor (C1-INH) effectively stabilized hemodynamics in three patients with severe reperfusion injury after coronary surgery. This novel rescue therapy facilitated recovery, enabling patients to be weaned from support and discharged.
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Background:
- Myocardial ischemia-reperfusion injury (IRI) is a significant complication following coronary revascularization.
- C1-esterase inhibitor (C1-INH) has shown cardioprotective effects in animal models of IRI.
- Limited clinical data exists on C1-INH use in severe IRI post-cardiac surgery.
Observation:
- Three patients experienced refractory hemodynamic compromise post-emergency surgical revascularization despite maximal conventional support.
- C1-esterase inhibitor (C1-INH) was administered as a last-resort rescue therapy.
- Patients received a 2000 U bolus followed by 1000 U at 12 and 24 hours.
Findings:
- C1-INH administration led to rapid hemodynamic stabilization in all three patients.
- Patients were successfully weaned from aortic counterpulsation and inotropic support within 24 hours.
- All treated patients survived and were discharged from the hospital.
Implications:
- C1-INH appears to be a promising adjuvant therapy for severe reperfusion injury in cardiac surgery.
- Blocking the complement cascade with C1-INH may restore myocardial function.
- These findings warrant controlled studies on prophylactic C1-INH use in high-risk cardiac surgery patients.
Abstract:
Administration of C1-esterase inhibitor (C1-INH) attenuates myocardial necrosis and sustains normal cardiac performance after myocardial ischemia and reperfusion in animal experiments. We report on our first experience of C1-INH application as rescue therapy in patients undergoing emergency surgical revascularization after failed percutaneous transluminal coronary angioplasty. Three patients were treated, because post-operative hemodynamic stabilization could not be achieved despite prolonged reperfusion periods, high-dose inotropic support, inodilators and aortic counterpulsation. As there was no surgical or medical option remaining, C1-INH was administered starting with a 2000 unit bolus, followed by 1000 U 12 and 24 h after surgery. C1-INH therapy resulted in rapid hemodynamic stabilization of all patients; weaning from aortic counterpulsation and epinephrine support was possible within 1 day. All patients survived and were discharged from hospital. In this group of patients suffering from severe reperfusion injury after coronary surgery, C1-INH seemed to be an effective adjuvant therapy to restore myocardial function by blocking the complement cascade. These results should encourage the performance of controlled studies on the effects of prophylactic C1-INH substitution therapy in patients undergoing coronary surgery at high risk conditions.